C14orf182 inhibitors encompass a variety of compounds that exert their inhibitory effects through different mechanisms, primarily by interfering with kinase activity and signaling pathways. The inhibition of kinase activity can be achieved by compounds that directly suppress the catalytic activity necessary for phosphorylation, a post-translational modification that C14orf182 relies on for its function. Some of these compounds form a complex with the ATP-binding site of kinases, thereby preventing ATP from binding and transferring a phosphate group to C14orf182. This interruption in phosphorylation cascades directly diminishes the functional activity of C14orf182, as it may be dependent on such modifications for its stability, localization, or interaction with other cellular proteins.
Moreover, the activity of C14orf182 can be indirectly influenced by compounds that target signaling pathways upstream of C14orf182. Inhibition of these pathways results in a downstream effect that reduces the phosphorylation status of C14orf182, affecting its activity. For instance, compounds that inhibit the mTOR pathway lead to a broader suppression of protein synthesis, which could downregulate the expression levels and, consequently, the activity of C14orf182. Similarly, compounds that target other signaling molecules, such as PI3K, MEK, or p38 MAPK, disrupt the cascade of events that regulate the phosphorylation and activation of C14orf182.
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
A potent kinase inhibitor that can suppress the phosphorylation process. C14orf182, being a kinase, can have its activity inhibited by this compound. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
An mTOR inhibitor that can downregulate protein synthesis by inhibiting the mTOR pathway, leading to reduced activity of C14orf182. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
A PI3K inhibitor that would lead to a decrease in Akt signaling, which may affect the phosphorylation status and activity of C14orf182. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
A MEK inhibitor that could prevent the activation of the MAPK/ERK pathway, reducing the phosphorylation and function of C14orf182. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
A p38 MAPK inhibitor, which may disrupt the p38 pathway and thereby decrease the phosphorylation-dependent activity of C14orf182. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
An inhibitor of JNK, which could lead to reduced stress-activated protein kinase signaling affecting the functional state of C14orf182. | ||||||
WZ4003 | 1214265-58-3 | sc-473979 | 5 mg | $300.00 | ||
A selective NUAK1 inhibitor that could diminish the activity of kinases within the AMPK pathway, inhibiting the activity of C14orf182. | ||||||
BIX 02189 | 1094614-85-3 | sc-364436 sc-364436A | 5 mg 10 mg | $220.00 $378.00 | 5 | |
A selective inhibitor of MEK5, which might reduce the activity of ERK5 and thus the functional activity of C14orf182. | ||||||
GSK 2334470 | 1227911-45-6 | sc-364501 sc-364501A | 10 mg 50 mg | $195.00 $1142.00 | 1 | |
A selective PDK1 inhibitor, leading to reduced AGC kinase activity, which could indirectly inhibit the phosphorylation of C14orf182. | ||||||
AZD8055 | 1009298-09-2 | sc-364424 sc-364424A | 10 mg 50 mg | $160.00 $345.00 | 12 | |
An ATP-competitive inhibitor of mTOR, which would suppress its kinase activity, leading to decreased functional regulation of C14orf182. | ||||||